<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00901147</url>
  </required_header>
  <id_info>
    <org_study_id>SGH651</org_study_id>
    <secondary_id>SHF/CTG023/2008</secondary_id>
    <nct_id>NCT00901147</nct_id>
  </id_info>
  <brief_title>Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma</brief_title>
  <official_title>An Open-label Phase 2 Study of Intravenous Bortezomib and Oral Panobinostat (LBH589) in Adult Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma After Failure of Conventional Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Singapore General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Singapore General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether intravenous Bortezomib combined with oral&#xD;
      Panobinostat (LBH589) are effective in treating adult patients with relapsed/refractory&#xD;
      peripheral T-cell lymphoma or NK/T-cell lymphoma after the failure of conventional&#xD;
      chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Peripheral T-cell lymphoma (PTCL) and NK/T-cell lymphoma are uncommon diseases that are&#xD;
      prevalent in Asia. They are associated with poor prognosis when treated with conventional&#xD;
      chemotherapeutic regimes. Their long term disease-free survivals are dismal with only 10-30%&#xD;
      of patients surviving long term. More intensive regimens including high dose chemotherapy&#xD;
      with autologous stem cell transplant have been tried as primary induction treatment, but have&#xD;
      not been shown to be beneficial. Given the rarity of PTCL and NK/T-cell lymphoma, much of the&#xD;
      literature consists of studies with small sample size and anecdotal case reports. Therefore,&#xD;
      no consensus exists on the best therapeutic strategy for either newly diagnosed or relapsed&#xD;
      disease. The failure of conventional chemotherapy in this regard suggests that novel&#xD;
      therapies including epigenetic approaches and proteasome inhibition should be explored.&#xD;
&#xD;
      Preclinical data of bortezomib and histone deacetylase inhibitors (HDIs) in T-cell and&#xD;
      NK/T-cell lymphoma cell lines are encouraging. Bortezomib and HDIs have also separately&#xD;
      demonstrated activity in T and NK/T-cell lymphomas in phase II studies, leading to their&#xD;
      separate developments in phase III studies. Demonstration of synergism in these 2 agents, in&#xD;
      part due to their dependence on overlapping pathways, suggests that they should be explored&#xD;
      as a combination, especially when treating a disease with a very unfavourable outcome. The&#xD;
      purpose of this phase II study is to assess the efficacy of orally-administered panobinostat,&#xD;
      a potent class I/II pan-deacetylase inhibitor with intravenous bortezomib in this patient&#xD;
      population.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to response, Duration of response, Progression-free survival, Overall survival, Safety and tolerability, Changes in disease-related symptoms and ECOG performance status.</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Peripheral T-cell Lymphoma (Not Otherwise Specified)</condition>
  <condition>Angioimmunoblastic T-cell Lymphoma</condition>
  <condition>Extranodal NK/T-cell Lymphoma Nasal Type</condition>
  <condition>Enteropathy- Type T-cell Lymphoma</condition>
  <condition>Hepatosplenic T-cell Lymphoma</condition>
  <condition>Anaplastic Large Cell Lymphoma (ALCL) (ALK-1 Negative)</condition>
  <condition>Relapsed ALCL (ALK-1 Positive) Post Autologous Transplant</condition>
  <arm_group>
    <arm_group_label>panobinostat and bortezomib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral Panobinostat and intravenous bortezomib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>panobinostat and bortezomib</intervention_name>
    <description>oral panobinostat 30 mg 3 times per week AND intravenous bortezomib 1.3mg/m2 on days 1,4,8,11 per cycle</description>
    <arm_group_label>panobinostat and bortezomib</arm_group_label>
    <other_name>LBH589B</other_name>
    <other_name>Velcade</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed PTCL NOS, angioimmunoblastic T-cell lymphoma, extranodal&#xD;
             NK/T-cell lymphoma nasal type, enteropathy- type T-cell lymphoma, hepatosplenic T-cell&#xD;
             lymphoma, ALCL (ALK-1 negative), or patients with ALK 1 expressing ALCL (ALK-1&#xD;
             positive) who have relapsed disease after ASCT&#xD;
&#xD;
          -  Age ≥21 years&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Progressive disease following at least one systemic therapy or refractory to at least&#xD;
             one prior systemic therapy&#xD;
&#xD;
          -  Measurable disease according to the IWC criteria and/or measurable bone marrow disease&#xD;
             by flow cytometry or morphology&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-2&#xD;
&#xD;
          -  Absolute neutrophil count of ≥1000 × 10(9)cells/L&#xD;
&#xD;
          -  Serum potassium ≥3.8 mmol/L and magnesium ≥0.85 mmol/L (electrolyte abnormalities can&#xD;
             be corrected with supplementation to meet inclusion criteria)&#xD;
&#xD;
          -  Negative urine or serum pregnancy test on females of childbearing potential&#xD;
&#xD;
          -  All females of childbearing potential and males must use an effective barrier method&#xD;
             of contraception during the treatment period and for at least 1 month thereafter.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Chemotherapy or immunotherapy within 3 weeks of study entry&#xD;
&#xD;
          -  Concomitant use of any other anti-cancer therapy&#xD;
&#xD;
          -  Concomitant use of any other investigational agent&#xD;
&#xD;
          -  Any known cardiac abnormalities such as:&#xD;
&#xD;
               -  Congenital long QT syndrome;&#xD;
&#xD;
               -  QTcF interval &gt;480 milliseconds (msec);&#xD;
&#xD;
               -  A myocardial infarction within 12 months of study entry;&#xD;
&#xD;
               -  Other significant ECG abnormalities including 2nd atrio-ventricular (AV) block&#xD;
                  type II, 3rd degree AV block, or bradycardia (ventricular rate &lt; 50 beats/ min).&#xD;
&#xD;
               -  An ECG recorded at screening showing significant ST depression (ST depression of&#xD;
                  ≥2 mm, measured from isoelectric line to the ST segment at a point 60 msec at the&#xD;
                  end of the QRS complex). If in any doubt, the patient should have a stress&#xD;
                  imaging study and, if abnormal, angiography to define whether or not CAD is&#xD;
                  present;&#xD;
&#xD;
               -  Congestive heart failure (CHF) that meets New York Heart Association (NYHA) Class&#xD;
                  II to IV definitions and/or ejection fraction &lt;40% by MUGA scan or &lt;50% by&#xD;
                  echocardiogram and/or MRI;&#xD;
&#xD;
               -  A known history of sustained ventricular tachycardia (VT), ventricular&#xD;
                  fibrillation (VF), Torsade de Pointes, or cardiac arrest unless currently&#xD;
                  addressed with an automatic implantable cardioverter defibrillator (AICD);&#xD;
&#xD;
               -  Hypertrophic cardiomyopathy or restrictive cardiomyopathy from prior treatment or&#xD;
                  other causes (if in doubt, see ejection fraction criteria above);&#xD;
&#xD;
               -  Any cardiac arrhythmia requiring anti-arrhythmic medication;&#xD;
&#xD;
          -  Serum potassium &lt;3.8 mmol/L or serum magnesium &lt;0.85 mmol/L (electrolyte abnormalities&#xD;
             can be corrected with supplementation to meet inclusion criteria)&#xD;
&#xD;
          -  Concomitant use of drugs that may cause a prolongation of the QTcF&#xD;
&#xD;
          -  Concomitant use of CYP3A4 inhibitors&#xD;
&#xD;
          -  Impaired liver, renal or other organ function not caused by lymphoma, which will&#xD;
             interfere with the treatment schedule&#xD;
&#xD;
          -  Concomitant use of warfarin due to a potential drug interaction&#xD;
&#xD;
          -  Clinically significant active infection&#xD;
&#xD;
          -  Known infection with human immunodeficiency virus (HIV)&#xD;
&#xD;
          -  Patient has known clinically active hepatitis B or C&#xD;
&#xD;
          -  Previous extensive radiotherapy involving ≥30% of bone marrow (e.g., whole pelvis,&#xD;
             half spine), excluding patients who have had total body irradiation as part of a&#xD;
             conditioning regimen for stem cell transplant&#xD;
&#xD;
          -  Major surgery within 2 weeks of study entry&#xD;
&#xD;
          -  Peripheral neuropathy or neuropathic pain of Grade 2 or worse&#xD;
&#xD;
          -  Platelet count &lt;50 × 109 cells/L or platelet count &lt;30 × 109 cells/L if bone marrow&#xD;
             disease involvement is documented&#xD;
&#xD;
          -  Serum creatinine &gt;2.0 × ULN&#xD;
&#xD;
          -  Patients who are pregnant or breast-feeding&#xD;
&#xD;
          -  Patient has known hypersensitivity to any components of bortezomib (such as boron,&#xD;
             mannitol), or panobinostat&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yeow Tee Goh, MBBS MMed</last_name>
    <role>Principal Investigator</role>
    <affiliation>Singapore General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Darryl Tan, MBBS MMED</last_name>
    <role>Study Chair</role>
    <affiliation>Singapore General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Samsung Medical Centre</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Subang Jaya Medical Centre</name>
      <address>
        <city>Subang Jaya</city>
        <state>Selangor</state>
        <zip>47500</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universiti Kebangsaan Malaysia ( HUKM )</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>56000</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Center</name>
      <address>
        <city>Singapore</city>
        <zip>169608</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Singapore General Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>169608</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
    <country>Malaysia</country>
    <country>Singapore</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <study_first_submitted>May 11, 2009</study_first_submitted>
  <study_first_submitted_qc>May 12, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2009</study_first_posted>
  <last_update_submitted>June 26, 2014</last_update_submitted>
  <last_update_submitted_qc>June 26, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 27, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>t-cell lymphoma</keyword>
  <keyword>peripheral t-cell lymphoma</keyword>
  <keyword>nk/t-cell lymphoma, nasal type</keyword>
  <keyword>bortezomib</keyword>
  <keyword>velcade</keyword>
  <keyword>panobinostat</keyword>
  <keyword>LBH589b</keyword>
  <keyword>histone deacetylase inhibitor</keyword>
  <keyword>proteasome inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Peripheral</mesh_term>
    <mesh_term>Lymphoma, Large-Cell, Anaplastic</mesh_term>
    <mesh_term>Lymphoma, Extranodal NK-T-Cell</mesh_term>
    <mesh_term>Enteropathy-Associated T-Cell Lymphoma</mesh_term>
    <mesh_term>Immunoblastic Lymphadenopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Panobinostat</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

